Mangoceuticals マネジメント

マネジメント基準チェック /24

Mangoceuticalsの CEO はJacob Cohenで、 Oct2021年に任命され、の在任期間は 3.08年です。の年間総報酬は$ 640.24Kで、 40.6%給与と59.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の24.33%を直接所有しており、その価値は$ 1.59M 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と2.1年です。

主要情報

Jacob Cohen

最高経営責任者

US$640.2k

報酬総額

CEO給与比率	40.6%
CEO在任期間	3.1yrs
CEOの所有権	24.3%
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	2.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Mangoceuticals の収益と比較して、Jacob Cohen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$9m
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$640k	US$260k	-US$9m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$633k	US$70k	-US$2m

報酬と市場: Jacobの総報酬 ($USD 640.24K ) は、 US市場 ($USD 646.00K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jacobの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Jacob Cohen (45 yo)

3.1yrs

在職期間

US$640,238

報酬

Mr. Jacob D. Cohen served as an Executive Vice President of Metiscan, Inc. since joining in August 2008 until July 2011 and also served as Executive Vice President of its subsidiary, Taptopia, Inc. He is E...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jacob Cohen	Co-Founder	3.1yrs	US$640.24k	24.33% $ 1.6m
Eugene Johnston	Chief Financial Officer	2.1yrs	US$56.50k	1.54% $ 100.4k
Amanda Hammer	Chief Operating Officer	1.5yrs	US$329.43k	0.47% $ 30.6k

2.1yrs

平均在職期間

45yo

平均年齢

経験豊富な経営陣: MGRXの経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jacob Cohen	Co-Founder	3.1yrs	US$640.24k	24.33% $ 1.6m
Alexander Hamilton	Independent Director	2.1yrs	データなし	0.067% $ 4.4k
Lorraine D'Alessio	Independent Director	2.1yrs	データなし	0.47% $ 30.6k
Kenny Myers	Independent Director	2.1yrs	データなし	0.47% $ 30.6k
Brian Rudman	Chairman of the Advisory Board	1.8yrs	データなし	データなし
Aaron Andrew	Member of Advisory Board	1.5yrs	データなし	データなし
Douglas Christianson	Advisory Board Member	less than a year	データなし	データなし

2.1yrs

平均在職期間

45yo

平均年齢

経験豊富なボード: MGRXの取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Mangoceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

High number of new and inexperienced directors

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Recent updates

Third quarter 2024 earnings released: US$0.99 loss per share (vs US$1.70 loss in 3Q 2023)

Mangoceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Mangoceuticals, Inc. Launches 'Slim' Oral Semaglutide Weight Loss Treatment

Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)

Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023)

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

Mangoceuticals, Inc. Provides Non-Compliance Update

New major risk - Shareholder dilution

New major risk - Financial position

Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment

Mangoceuticals, Inc. Accepting Pre Orders for its PRIME

High number of new and inexperienced directors

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

New major risk - Market cap size

Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24